There was a DOH Advisory Council on the Implementation of RA 9502 (Cheaper Medicines Act of 2008) last April 20, 2015 that I was not able to attend. The Secretariat failed to invite me, but at least they sent me the minutes of the meeting, Among the speakers that day was Atty. Allan Gepte of the Intellectual Property Office (IPO), DTI and he was asked to give updates about the US (and PH?) Free Trade Agreement (FTA) and the European FTA (EFTA). He said that he was not aware of any current (PH-) USFTA negotiations and there are talks among EFTA countries.
He gave some updates about IP concerns in the country instead, like the DTI-IPO-DOH public consultation on IP issues, with some NGOs last March 31, 2015. The topics covered data protection patent term extensions. I was not there in that meeting.
But I have attended the same DTI-IPO-DOH meeting last June 04, 2015 at the DTI International building. It was chaired
by DTI Assistant Sec Rodolfo, IPO Dep. Allan Gepte, and DOH-NCPAM Doc Meme Guerrero. I learned about the meeting because three days ahead, June 01, there was another anti-TPP, anti-IPR forum at PRRM, QC, sponsored by IDEALS, MAG, AGAP and CHAT, and the speaker was Dr. Burku Kilik of Public Citizens, an NGO in the US. Then there was a belated invite to attend the March 31 meeting at the DTI.
I think it was a limited consultation because only very few NGOs were there, led perhaps by the Focus on the Global
South (FGS) leader, Joseph Purugganan, plus the Fair Trade Alliance, they are
campaigning against strong IPR protection in the non-existent EU-PH FTA or non-existent
PH membership in the TPP.
At the DTI consultation (a few CHAT members were also
there, also Dave Escalona of Unilab), I commented that the PH is not even among the invited members
of the TPP (only 4 of 10 ASEAN countries were invited to the TPP) and yet there
are a number of noise against those proposed FTAs the issue of
IPR.
Assuming for the sake of arguments that (1) there is
a TPP Agreement already today or tomorrow, (2) the PH is a member of TPPA, and
(3) all those "dreaded data exclusivity", etc. provisions are
implemented -- then they will affect only a few, newly-invented medicines and
not the 90-99% of off-patent, useful generic medicines in the WHO and DOH
essential medicines list (EML). I think anti-IPR campaigners are not aware of
this, perhaps they think that any extended regulatory data protection (RDP) and
patent protection on innovator drugs also apply to off-patent, generic drugs.
Far out, man.
"data exclusivity can apply to
off-patent, or even non-patented, drugs. Patent protection is different from
data exclusivity but both seek to prevent the entry of generic competition and
preserve the monopoly status of the originator. The only difference is patent
protection is protected by TRIPs while data exclusivity is TRIPS Plus. Data
exclusivity is NOT required by WTO. This is why the US tries to insert it in
bilateral or multilateral trade agreements."
I thanked Joey for his comments. These are legal matters, outside my usual cup of coffee
so I yield to his explanation.
For now, the PH government through DTI Sec. Domingo has
officially signified its intention to join the TPP in the next round of
membership expansion. I support this move, I believe that it is not possible
for the PH to have a bilateral FTA with the US or even Canada, and the US will
remain to be the biggest, most innovative economy in the planet for the next decade or two. The
only way to have an FTA with them is through the TPP.
If what Joey mentioned that data exclusivity is to
"prevent the entry of generic competition", then it will have a rough
sailing in the PH as access to generics is both a health and emotional issue
here and in many other countries.
Things like this, the AC can discuss as RA 9502 is first
and foremost, about IPC amendment and price regulation is just an add-on or
after-thought chapter in the law. I have attended 2 fora already about TPP and
IPR involving 2 foreign speakers who are generally anti-IPR and both facilitated by IDEALS and CHAT. The
first was a lady speaker from France, the 2nd was another lady speaker from the
US, from Global Citizen. The 2 fora did not have legal minds as discussants
after the presentation.
-----------
See also:
IPR and Medicines 32: The Policy Workshop's Hong Kong Dialogue, November 28, 2015
IPR and Medicines 35, New paper from Geneva Network, July 17, 2015
No comments:
Post a Comment